Scaling biotech and improving global health: lessons from an extraordinary career in medicine | Susan Desmond-Hellmann, M.D., M.P.H.

Peter Attia

Apr 28, 2025

Episode description

View the Show Notes Page for This Episode

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter’s Weekly Newsletter

Susan Desmond-Hellmann is a physician and scientist whose remarkable career has spanned clinical medicine, oncology, biotech innovation, and global health leadership. In this episode, Susan shares insights from her journey training in internal medicine during the early AIDS crisis, treating HIV-related cancers in Uganda, and developing groundbreaking cancer therapies like Herceptin and Avastin. She reflects on her leadership roles at UCSF and the Bill and Melinda Gates Foundation, offering lessons on guiding large-scale health initiatives, navigating uncertainty, and fostering scientific innovation. The conversation explores the promise of precision medicine, the integration of patient care and policy, and the evolving role of artificial intelligence in transforming diagnostics, drug development, and global access to care.

We discuss:

  • Susan’s medical training, the start of the AIDS epidemic, and the transformative experiences that shaped her career [3:00];

  • Susan’s experience working on the frontlines of the HIV/AIDS crisis in Uganda [12:30];

  • Susan’s time working in general oncology and her transition to biotech where she helped develop taxol—a top-selling cancer drug [26:30];

  • Genentech’s origins, and its groundbreaking use of recombinant DNA to develop biologic drugs [33:45];

  • Susan’s move to Genentech, and her pivotal role in the development and success of Herceptin as a groundbreaking therapy in targeted oncology [44:00];

  • The rise of antibody-based cancer therapies: the development of Rituxan and Avastin [52:15];

  • The step-by-step drug development process and the scientific and strategic challenges involved [1:01:30];

  • The ethical and economic controversy surrounding Avastin’s high cost and limited survival benefit [1:12:30];

  • Susan’s tenure as chancellor at UCSF: leading during a financially strained period, and her strategic approach to fundraising and institutional development [1:14:45];

  • What Susan learned as CEO of the Bill and Melinda Gates Foundation: strategic processes and decision-making frameworks [1:26:00];

  • Susan’s philosophy of leadership and how she sought to build a

Episode description

View the Show Notes Page for This Episode

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter’s Weekly Newsletter

Susan Desmond-Hellmann is a physician and scientist whose remarkable career has spanned clinical medicine, oncology, biotech innovation, and global health leadership. In this episode, Susan shares insights from her journey training in internal medicine during the early AIDS crisis, treating HIV-related cancers in Uganda, and developing groundbreaking cancer therapies like Herceptin and Avastin. She reflects on her leadership roles at UCSF and the Bill and Melinda Gates Foundation, offering lessons on guiding large-scale health initiatives, navigating uncertainty, and fostering scientific innovation. The conversation explores the promise of precision medicine, the integration of patient care and policy, and the evolving role of artificial intelligence in transforming diagnostics, drug development, and global access to care.

We discuss:

  • Susan’s medical training, the start of the AIDS epidemic, and the transformative experiences that shaped her career [3:00];

  • Susan’s experience working on the frontlines of the HIV/AIDS crisis in Uganda [12:30];

  • Susan’s time working in general oncology and her transition to biotech where she helped develop taxol—a top-selling cancer drug [26:30];

  • Genentech’s origins, and its groundbreaking use of recombinant DNA to develop biologic drugs [33:45];

  • Susan’s move to Genentech, and her pivotal role in the development and success of Herceptin as a groundbreaking therapy in targeted oncology [44:00];

  • The rise of antibody-based cancer therapies: the development of Rituxan and Avastin [52:15];

  • The step-by-step drug development process and the scientific and strategic challenges involved [1:01:30];

  • The ethical and economic controversy surrounding Avastin’s high cost and limited survival benefit [1:12:30];

  • Susan’s tenure as chancellor at UCSF: leading during a financially strained period, and her strategic approach to fundraising and institutional development [1:14:45];

  • What Susan learned as CEO of the Bill and Melinda Gates Foundation: strategic processes and decision-making frameworks [1:26:00];

  • Susan’s philosophy of leadership and how she sought to build a

Mindsip insights from this episode:

Establish company culture through moments of truth

Company culture is defined in moments of truth, such as senior leaders instinctively rejecting a proposal to use a less accurate test to increase revenue.

Recognize tumor lysis syndrome as a sign of Rituxan's effectiveness

When the lymphoma drug Rituxan caused cells to break down so fast that kidneys failed (tumor lysis syndrome), it was a clear sign that the antibody was an incredibly powerful and effective drug.

Reapply antibody drugs for effective cancer treatment after recurrence

Unlike chemotherapy, if a cancer comes back after being treated with an antibody drug like Herceptin or Rituxan, you can often successfully use the same antibody again.

Develop commercial diagnostic tests alongside breakthrough drugs

The approval of the breakthrough cancer drug Herceptin was delayed because the company failed to develop the required commercial diagnostic test in parallel with the drug itself.

Identify Kaposi's sarcoma as definitive HIV indicator

In resource-limited 1980s Uganda, the presence of Kaposi's sarcoma on the soft palate was a 100% predictive sign of having HIV.

Rebuild public trust to prepare for future pandemics

A top global health expert is "absolutely horrified" and believes that if another pandemic happened today, the outcome would be even worse due to a breakdown in public trust.

Accelerate drug approval timelines with AI

Artificial intelligence has the potential to reduce the drug approval timeline by two years, not by changing the core science, but by accelerating the laborious paperwork and reporting processes.

Identify simple biomarkers to accelerate disease cures

The key to accelerating cures for diseases like cancer is to find a simple biomarker, similar to how "viral load" revolutionized HIV treatment by allowing for rapid testing of new drugs.

Question liquid biopsies for reliable cancer detection

Despite the hype, current liquid biopsies for early cancer detection are viewed negatively by some experts because the data suggests tumors simply don't shed enough DNA to be reliably detected.

DOWNLOAD THE APP

Unlock the wisdom of longevity

DOWNLOAD THE APP

Unlock the wisdom of longevity

DOWNLOAD THE APP

Unlock the wisdom of longevity

Unlock the wisdom of longevity

© Mindsip 2025 – Made with ❤ in Vilnius

Unlock the wisdom of longevity

© Mindsip 2025 – Made with ❤ in Vilnius